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Abstract
Purpose of Review Hematopoietic cell transplantation (HCT) is an established curative treatment for children with primary
immunodeficiencies. This article reviews the latest developments in conditioning regimens for primary immunodeficiency
(PID). It focuses on data regarding transplant outcomes according to newer reduced toxicity conditioning regimens used in
HCT for PID.
Recent Findings Conventional myeloablative conditioning regimens are associated with significant acute toxicities, transplant-
related mortality, and late effects such as infertility. Reduced toxicity conditioning regimens have had significant positive impacts
on HCT outcome, and there are now well-established strategies in children with PID. Treosulfan has emerged as a promising
preparative agent. Use of a peripheral stem cell source has been shown to be associated with better donor chimerism in patients
receiving reduced toxicity conditioning. Minimal conditioning regimens using monoclonal antibodies are in clinical trials with
promising results thus far.
Summary Reduced toxicity conditioning has emerged as standard of care for PID and has resulted in improved transplant
survival for patients with significant comorbidities.
Keywords Primary immunodeficiency . Hematopoietic cell transplantation . Reduced toxicity conditioning . HCT outcome .
Transplant-related survival
Introduction
Primary immunodeficiency (PID) comprises a large, hetero-
geneous group of disorders that result from defects in immune
system development and/or function. Long considered as rare
diseases, recent studies show that one in 2000–5000 children
younger than 18 years is thought to have a PID. There are now
around 350 single-gene inborn errors of immunity and the
underlying phenotypes are as diverse as infection, malignan-
cy, allergy, autoimmunity, and autoinflammation. Therefore,
presenting features, severity, and age of diagnosis vary im-
mensely. Hematopoietic cell transplantation (HCT) is a well-
recognized curative therapy for many of these PIDs. Since the
first transplant took place in 1968, utility of HCTwas initially
limited by high rates of graft failure and transplant-related
morbidity and mortality; however, transplant survival and
graft outcomes have significantly improved, particularly since
2000 [1, 2]. Many factors have contributed to this improve-
ment including earlier diagnosis, a detailed graft selection hi-
erarchy, superior HLA matching technology, improved
methods for graft manipulation, greater availability of grafts,
improved supportive care, vigilant infection surveillance and
pre-emptive treatment, and more effective antimicrobial ther-
apy. In the modern era, graft engineering, additional cellular
therapy, and pharmacokinetic-guided conditioning regimens
enable precise personalized transplant care including prescrip-
tion of graft components, better cell-dosed grafts, and a
patient-tailored conditioning regimen [3, 4•, 5••].
This article is part of the Topical Collection on Immune Deficiency and
Dysregulation
* M. A. Slatter
mary.slatter@nuth.nhs.uk
1 Children’s Haematopoietic Stem Cell Transplant Unit, Great North
Children’s Hospital, Newcastle upon Tyne Hospital NHS Foundation
Trust, Newcastle upon Tyne, UK
2 Department of Pediatrics, University Medical Center Ulm,
Ulm, Germany
3 Institute of Cellular Medicine, Newcastle University, Newcastle upon
Tyne, UK
Current Allergy and Asthma Reports           (2019) 19:52 
https://doi.org/10.1007/s11882-019-0883-1
Short-term transplant survival outcomes must be carefully
distinguished from long-term disease outcomes and late ef-
fects of transplant. As survival from transplant has improved,
more attention is now given to long-term disease outcomes
and quality of life. Therefore, the goal of conditioning is to
give the least toxic regimen with minimal short- and long-term
side effects but still achieve cure of the underlying condition.
This review will focus on newer conditioning regimens, how
they have changed, and possible future directions. It is impor-
tant to note that success does not simply depend on which
conditioning chemotherapeutic agents are employed but on a
combination of factors such as additional serotherapy, timing
and dosage, and stem cell source. In almost all cases, prepar-
ative conditioning with a combination of chemotherapeutic
agents, with or without monoclonal antibodies, is required
for successful engraftment and stable robust long-term im-
mune reconstitution.
Definition
The intensity of the conditioning regimen can vary sub-
stantially and has been classified as myeloablative condi-
tioning (MAC), reduced toxicity conditioning (RTC), re-
duced intensity conditioning (RIC), and minimal intensity
conditioning (MIC) in decreasing order (Fig. 1). MAC,
consisting of alkylating agents with or without total body
irradiation (TBI), is expected to myeloablate the recipi-
ent’s hematopoiesis which does not allow for autologous
hematological recovery. This aims to prevent rejection by
the use of supralethal chemotherapy to remove host-
versus-graft reaction and create marrow niche space for
donor stem cells. Newer myeloablative chemotherapy
agents are being explored to reduce toxicity and enable
safer HCT. These reduced toxicity conditioning (RTC)
regimens, including pharmacokinetic targeted busulfan-
fludarabine (Bu-Flu) and treosulfan-fludarabine, have a
comparable myeloablative effect with conventional MAC
but reduced organ toxicities. Compared to MAC, RIC has
been t r ad i t i ona l ly cha rac t e r i zed by reve r s ib l e
myelosuppression in the absence of stem cell rescue, re-
duced regimen-related toxicity, and a higher incidence of
mixed chimerism. MIC is strictly non-myeloablative, does
not eradicate host hematopoiesis, and allows relatively
rapid autologous hematopoietic recovery without a trans-
plant, but adequately myelosuppresses the recipient to en-
able at least partial donor engraftment.
Myeloablative Conditioning Regimens in PID
Historically, conditioning therapy prior to HCT in PID was
based on the combination of alkylators busulfan and
cyclophosphamide. However, many children with PID have
significant comorbidities at the time of HCT, and these con-
ventional myeloablative preparative regimens are associated
with significant toxicity and a relatively high incidence of
transplant mortality, as well as long-term sequelae. While ini-
tial results may have been acceptable, appreciation of acute
conditioning toxicities and recognition of long-term sequelae
mean that few centers now approach transplantation of PID
patients with conventional myeloablative preparative regi-
mens (Table 1) [6–9].
RTC Regimens in PID
The use of reduced toxicity conditioning regimens are now
generally preferred for patients with PID as there is no malig-
nant disease to eradicate, stable mixed chimerism achieves
cure for many diseases, and many patients enter HCT with
chronic infect ions and end-organ comorbidi t ies .
Additionally, many patients are infants at the time of trans-
plant and may be more susceptible to toxicity [10]. Less toxic
regimens may reduce early and late adverse effects, particu-
larly infertility [4•]. There are several reduced toxicity regi-
mens that have been utilized by investigators in PID (Table 2)
[14•, 49, 50].
Fludarabine and Treosulfan
Treosulfan (L-treitol-1,4-bis-methanesulfonate) is a prodrug
and a water-soluble bifunctional alkylating agent which has
been used for many years as treatment for various neoplasms,
but more recently as part of conditioning for HSCT. In addi-
tion to myeloablative properties, it has marked immunosup-
pressive properties which contribute to the achievement of
stable engraftment posttransplant. It causes relatively low or-
gan toxicity compared to high-dose busulfan and cyclophos-
phamide leading to fewer complications such as veno-
occlusive disease of the liver.
The first successful allogeneic transplant in a child using
treosulfan was performed in 2000 and since then many reports
have confirmed its efficacy and safety in both malignant and
non-malignant disorders [11••, 12•, 13, 14•, 15–18]. Slatter
et al. first published results of 70 children with PID who re-
ceived treosulfan in combination with either cyclophospha-
mide (n = 30) or fludarabine (n = 40) with an overall survival
of 81% (median follow-up 19 months) equivalent in those
aged less or greater than 1 year at time of transplant [13].
Toxicity was low but worse after cyclophosphamide, and T
cell chimerism was significantly better after fludarabine [18].
Slatter et al. more recently reported 160 patients who had
received conditioning with treosulfan and fludarabine achiev-
ing a probability of 2-year survival of 87.1% with a high level
of complete or stable mixed chimerism in the diseased cell
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lineage, sufficient to cure disease [11••]. There was a high
survival rate in children transplanted under 1 year of age in
whom toxicity can be a problem with conventional and other
reduced intensity conditioning regimens [24, 25]. A 100-day
survival of 94% demonstrated the low toxicity of this regimen
making it suitable for patients with PID who often have infec-
tion and organ damage prior to HCT. In this series, a higher
level of myeloid chimerism was found in recipients of PBSC
compared to CB and BM, without an increased risk of grade
III/IVacute or chronic graft-versus-host disease (GvHD). This
highlights the importance of the whole transplant package
including stem cell source and serotherapy when tailoring
therapy [26].
Excellent results were reported by Lehmberg et al. in 19
patients with hemophagocytic lymphohistiocytosis (HLH)
following HCT with treosulfan, fludarabine, alemtuzumab,
with or without thiotepa, all of whom survived with a median
follow-up of 16 months [16].
Haskologlu et al. reported 15 patients with PID who had a
high risk of developing transplant-related toxicity due to pre-
vious lung and liver damages and were given treosulfan-based
conditioning [27]. At 32 months follow-up, the overall surviv-
al was 86.7% with excellent chimerism and low conditioning
associated morbidity despite the high-risk population.
Mixed chimerism is sufficient to achieve cure in some non-
malignant disorders, but the specific diagnosis and level of
chimerism needed to achieve cure must be taken into account
when balancing the need for increased myeloablation against
short- and long-term toxicities from the conditioning regimen.
The addition of thiotepa is common in order to increase the
intensity of the regimen, but there are few reports of any com-
parison in outcomes comparing treosulfan and fludarabine
with or without additional thiotepa. Yael Dinur-Schejter
et al. reported 44 patients with non-malignant diseases: 19
received treosulfan with fludarabine 66.7% of whom achieved
complete engraftment compared to 94.7% of 20 patients who
received additional thiotepa, but this did not translate into any
significant difference in overall or event free survival [15].
Fludarabine and Busulfan
Traditionally, busulfan (Bu) was used in combination with
cyclophosphamide (Cy) as the standard myeloablative condi-
tioning regimen for HCT for both malignant and non-
malignant disorders in both adult and pediatric patients.
Cyclophosphamide is increasingly being substituted with
fludarabine (Flu), a nucleoside analogue with immunosup-
pressive properties, to provide a less toxic but equally effec-
tive regimen [19, 21, 28].
Harris et al. compared 1400 children who received Bu-Cy to
381 who received Bu-Flu. Busulfan doses were comparable be-
tween the 2 groups and the majority had pharmacokinetic mon-
itoring. Eight hundred and three had non-malignant disorders
including 195 with PID who received Bu-Cy and 86 who re-
ceived Bu-Flu. Nine hundred and seventy-eight had malignant
disorders. Children receiving Bu-Flu for non-malignant
Fig. 1 Intensity of conditioning regimen according to chemotherapy, pharmacokinetic guided dosing, timing of serotherapy, and combination of
chemotherapy
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conditions experienced less toxicity than those receiving Bu-Cy,
but survival was comparable. Children with malignancy had
shorter postrelapse survival with Bu-Flu than Bu-Cy although
transplant-related mortality and relapse were similar [29].
The pharmacokinetics of busulfan have been studied ex-
tensively and the use of a lower target area under the curve
(45–65 mg/L × h) combined with fludarabine has been
pioneered by Tayfun Güngör and colleagues in Zurich.
Particularly impressive results have been seen using this reg-
imen for patients with chronic granulomatous disease (CGD).
Fifty-six children and young adults with CGD were reported,
many of whom had high-risk features such as intractable in-
fections and autoinflammation. Twenty-one HLA-matched
related-donor and 35 HLA-matched unrelated-donor trans-
plants were done. The 2-year probability of overall survival
was 96% (95% CI 86∙46–99∙09), and of EFS was 91%
(79∙78–96∙17). Graft-failure occurred in 5% (three of 56) of
patients. The cumulative incidence of acute GvHD of grade
III–IV was 4% (two of 56) and of chronic GvHD was 7%
(four of 56). Stable (≥ 90%) myeloid donor chimerism was
documented in 52 (93%) surviving patients [20••].
Dvorak et al. have recently reported the result of the use
busulfan at a lower target area under the curve (30 mg/L × h)
alone or in combination with fludarabine or thiotepa in 10
patients with severe combined immunodeficiency. All the pa-
tients survived, one patient required second HCT, and 3 had
no B cell reconstitution [19].
RIC in PID
Fludarabine and Melphalan
Increasing recognition of the significant toxicities associated
with conventional doses of busulfan and cyclophosphamide,
particularly in very young infants and especially in those with
pre-existing end organ damage, led to the adoption of immu-
nosuppressive-based, rather than myelo-ablative-based regi-
mens, with fludarabine andmelphalan. The results, principally
in those with significant preexisting comorbidities, were strik-
ing with significantly improved early survival [22, 23, 30, 31,
49]. However, donor chimerism was not always optimal, and
there was a high incidence of late viral reactivation, and late
onset acute GvHD. Furthermore, toxicities in infants < 1 year
of age remained significant [25]. Melphalan in particular has
been associated with cardiac toxicities [32]. Good results have
been reported for pat ients with hemophagocyt ic
lymphohistiocytosis [33]. Patients with X-linked inhibitor of
apoptosis protein (XIAP) deficiency, which is difficult to
transplant, also have good outcomes reported using
fludarabine and melphalan-based regimens [34]. It has been
used in adults with PID with good transplant survival [23]
While the approach remains attractive in terms of reduced
toxicities, concerns regarding late graft failure and high mor-
tality in the < 12-month-aged infants remain.
Minimal Intensity Conditioning for PID
Fludarabine and Low-Dose TBI
Burroughs et al. from the Seattle group have reported the
transplant outcome of using fludarabine and low-dose TBI
in 14 PID patients with significant preexisting organ dysfunc-
tion and infections. All received posttransplant GvHD pro-
phylaxis with cyclosporin and mycophenolate mofetil but no
serotherapy. Overall survival at 3 years was 62%, but there
were high rates of acute (79%) and extensive chronic GvHD
(47%) [35]. One had graft failure and an additional three pa-
tients required a second procedure for decreasing chimerism.
Of 10 evaluable patients, 8 had correction of immune defi-
ciency with stable chimerism. However, the high rate of
GvHD has limited the broader use of this conditioning regi-
men in children with PID [35, 36].
Antibody-Based
While conditioning regimens have undoubtedly become less
toxic, the ability to achieve donor chimerism without the use
of chemotherapeutic agents, particularly in patients with non-
malignant disease, is extremely attractive. Furthermore, some
primary immunodeficiencies have significant toxicities asso-
ciated with the administration of alkylating agents, due to the
nature of the molecular defect, leading to serious long-term
effects or early mortality [37–39]. A number of different strat-
egies have been employed to minimize the exposure to che-
motherapeutic agents by the use of antibodies to aid stem cell
engraftment, with or without adjunct chemotherapy.
Anti-CD45 Antibodies
CD45 is selectively expressed on all leucocytes and hemato-
poietic progenitors but is absent on non-hematopoietic tissues.
Straathoff and colleagues studied 16 patients with PID who
were less than 1 year of age or had significant preexisting
comorbidities and were felt not suitable for conventional re-
duced intensity conditioning [24]. The conditioning regimen
was comprised of alemtuzumab 0.2 mg/kg daily for 3 days for
unrelated donors, or 0.1 mg/kg daily for 3 days for matched
sibling donors on day − 8 to day − 6, clinical grade rat anti-
CD45 (YTH24·5and54·12) 0.4 mg/kg on day − 5 to day − 2,
fludarabine (30 mg/m2 daily for 5 days on day − 8 to day − 4)
and cyclophosphamide (300 mg/m2 daily for 4 days on day −
7 to day − 4). Twelve patients were alive and well at the end of
the study, one failed to engraft and was successfully re-
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transplanted, and 3 died—none of conditioning toxicity.
Donor chimerism was variable but high level and sufficient
to cure disease in the survivors.
Radioimmunotherapy
Radioimmunotherapy is an attractive concept for conditioning
of patients with PIDs as it exploits of the physical cytotoxic
effect of radiation and reduces the toxicity to other organ sys-
tems by its internal application and the conjugation of radio-
isotopes to specific antibodies [40]. Radioisotopes emitting α,
β or γ-radiation of calculated intensity can be brought in
direct proximity to the cells of interest. This enables malignant
cells to be eradicated or benign hematopoietic cells to be de-
pleted as part of conditioning before autologous or allogeneic
HSCT. The method was developed to allow better and more
specific control of malignant cells in the setting of HSCT
without an increase in non-relapse mortality. Considerable
clinical data was accumulated with conjugates of 90Yttrium
or 131Iodine to anti-CD20 antibodies in the treatment of pa-
tients with refractory or recurrent B cell non-Hodgkin lym-
phoma (B-NHL). The drugs were used in combination with
chemotherapy to prepare patients for autologous and alloge-
neic stem cell transplantation. This experience resulted in the
approval of two drugs (Zevalin® and Bexxar®) by the FDA at
the beginning of the century [40].
The use of RIT for the treatment of leukemias or for
myeloablation in non-malignant disease until present is
limited to clinical studies. A conjugate of 131Iodine to
anti-CD45-antibody was explored in the treatment of pa-
tients with AML and high-risk MDS, again a combination
of RIT with conventional myeloablative or immunosup-
pressive drugs was used for conditioning before allogene-
ic HSCT [41, 42]. CD45 is expressed on most AML and
ALL blasts as well as on virtually all developing and
mature cells of normal hematopoiesis. Radiolabeled anti-
CD45 antibody doses up to 43 Gy were administered to
the bone marrow in combination with RIC and allogeneic
transplantation with good tolerance and without additional
toxicity in younger adult patients with AML and MDS
[43]. For children, limited published data exists for the
use of RIT for pretransplant conditioning. A conjugate
of 90Yttrium to an antibody targeting CD66 was used in
combination with melphalan and fludarabine or TBI for
the treatment of children with considerable comorbidities
with malignant and non-malignant disease. 90Yttrium
emits pure β-radiation with a maximum range of 11 mm
and a half-life of 2.7 days [44]. With these qualities, no
isolation of the pediatric patients was necessary, but the
dosimetry had to be performed with another isotope, emit-
ting γ-radiation to be detected in a γ-camera. CD66 is
abundantly present on mature myeloid cells but usually
not expressed on malignant blasts. The therapeutic
principle of RIT with this antibody in malignant disease
therefore relies on the so-called cross-fire effect, which
describes the indirect depletion of blasts by binding of
the antibody to cells in close proximity [40]. In order to
avoid graft rejection in unrelated or mismatched grafts,
recipients received serotherapy with ATG in this setting.
Fifteen of 16 children with non-malignant disease sur-
vived the procedure, 13/15 with complete donor chime-
rism. The Kaplan-Meier estimation for disease-free sur-
vival at 24 months was 94%. This clearly documented
feasibility of and reliable myeloablation by RIT in chil-
dren and young adults with non-malignant disease.
Anti-CD117 Antibodies
The molecule CD117 (c-Kit receptor) is expressed on he-
matopoietic stem cells at all stages of development.
Interactions with the ligand of CD117, stem cell factor,
are crucial for hematopoietic stem cell survival, and this
signaling pathway plays a critical role in the homing, ad-
hesion, maintenance, and survival of hematopoietic stem
cells in the hematopoietic niche. Preclinical studies dem-
onstrated that using an antibody against CD117 to impede
CD117-stem cell factor signaling selectively depleted he-
matopoietic stem cells with no effect on differentiated
progenitor or mature cell lineages, and enabled engraft-
ment of donor cells [45]. A clinical trial is currently in
progress using anti-CD117 antibody alone to treat patients
w i t h p r ima r y immunod e f i c i e n c i e s (AMG191
Conditioning/CD34 + CD90 Stem Cell Transplant Study
for SCID Patients, ClinicalTrials.gov Identif ier:
NCT02963064). The early results of this dose finding
study show that some donor stem cell chimerism,
leading to donor T and B lymphocyte chimerism can be
achieved [46]. These preliminary data are extremely
exciting and potentially lead the way to a step change in
approaches to conditioning in patients with PIDs.
Conditioning for Haploidentical Donor
Transplant
As the outcomes of HCT using newer T cell depletion
methods have improved, there is an increasing number of
haploidentical transplants performed for both SCID and
non-SCID PID. Various non-myeloablative conditioning
regimens have been used in T-deplete and T-replete
haploidentical transplant (Table 3) [5••, 47, 48, 51]. The
Great North Children’s Hospital (GNCH) group in
Newcastle has used fludarabine, treosulfan, ATG
(Grafalon), and ritixumab for patients who received CD3
TCR ab/CD19 depleted peripheral blood stem cells.
Patients with non-SCID PID received additional thiotepa.
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The overall survival was comparable with family and un-
related donor transplant using a similar conditioning regi-
men [18, 51]. Neven et al. reported the outcome of Bu-Flu
in 22 patients with PID received haploidentical transplant
using posttransplant cyclophosphamide. The overall sur-
vival and donor chimerism were good, but 48% had acute
GvHD and 24.2% had chronic GvHD.
Pharmacokinetic Studies
Although levels of busulfan have been measured for many
years, to target the narrow myeloablative therapeutic window,
minimize toxicity from supra-therapeutic levels and avoid
sub-myelo-ablation and rejection, it is only recently that the
importance of pharmacokinetic monitoring of other agents of
the conditioning cocktail has been appreciated.
Fludarabine Pharmacokinetics
Ivaturi et al. prospectively studied the pharmacokinetics
and pharmacodynamics of 133 children undergoing HCT
for a variety of disorders with a variety of conditioning
regimens but all included fludarabine. Young age and re-
nal impairment were found to lead to an increased expo-
sure. In the setting of malignancy, disease-free survival
(DFS) was highest 1 year after HCT in subjects achieving
a systemic fludarabine plasma (f-ara-a) cumulative area
under the curve (cAUC) greater than 15 mg*hour/L com-
pared to patients with a cAUC less than 15 mg*hour/L
(82.6% versus 52.8%, p = 0.04) [52]. Further development
of model-based dosing may minimize toxicity and maxi-
mize efficacy, resulting in superior outcomes for malig-
nant and non-malignant patients.
Treosulfan Pharmacokinetics
Relatively high variability of treosulfan pharmacokinetics
in pediatric patients may raise the need for implementing
therapeutic drug monitoring and individual dose adjust-
ment in this group. Vander Stoep et al. and Mohanan
et al. recently published the first results of a relationship
between the exposure of treosulfan and early toxicity, as
well as clinical outcome, in children undergoing condi-
tioning prior to HSCT. In the former study, patients with
an AUC > 1650 mg h/L demonstrated a statistically higher
incidence of mucosal and skin toxicity than those with an
AUC 1350 mg h/L (odds ratio 4.4 and 4.5, respectively).
The odds of developing hepato- and neurotoxicity were
also higher in the former group, but the difference did not
reach statistical significance. No association was found
between treosulfan exposure and early clinical outcomes,
i.e., engraftment, donor chimerism, acute graft-versus-
host disease, treatment-related mortality, and overall sur-
vival. PK parameters were shown to be age-dependent,
with higher AUC values in younger children (< 1 year
old) and corresponding lower treosulfan clearance. A
challenge in therapeutic monitoring of treosulfan within
conditioning prior to HCT is a very brief course of treat-
ment, consisting of three doses administered on 3 consec-
utive days. This allows personalization of only the second
and third dose of the prodrug unless a test dose is applied
prior to starting the actual regimen.
Since pharmacokinetic studies of treosulfan began, it
has been assumed that plasma (serum) concentrations of
the prodrug are a good representation of the alkylating
activity of its epoxy transformers. However, for years, a
correlation between treosulfan concentrations in plasma
and levels of specific DNA adducts in tissues, for exam-
ple the bone marrow, or clinical effects, have not been
investigated. Therapeutic drug monitoring of not only
prodrug but also its active epoxide might be needed. In
addition blood pH, body temperature, and intravenous
fluid delivery may influence glomerular filtration, tubular
reabsorption, and nonenzymatic epoxy transformation of
the prodrug [53].
Serotherapy Levels
It is now well recognized that type of serotherapy, dose
and timing in relation to the transplant all have an impact
on outcome of transplant in terms of occurrence of
GVHD, immune reconstitution importantly in terms of
viral reactivation, clearance of infection, and chimerism.
Marsh RA et al. collected data from 105 patients to ex-
amine the influence of peritransplant alemtuzumab levels
on acute GVHD, mixed chimerism, and lymphocyte re-
covery. Significantly higher levels of aGVHD but higher
levels of donor chimerism, lymphocyte counts at D+30
and T cell counts at D+100 were associated with lower
alemtuzumab levels at day 0 [54].
In a recent report, the clearance of the active compo-
nents of the 2 widely used types of ATG (Fresenius/
Grafalon and Genzyme) was studied in 38 children with
malignant hematological disorders. They found that ATG
Fresenius was cleared rapidly and uniformly from the
circulation whether they received 60 mg/kg or 45 mg/kg,
but there were significant differences in patients who re-
ceived a high dose of ATG Genzyme (10 mg/kg) who
had significantly slower reconstitution for CD3, CD4,
and CD8 T cells compared to patients who received a
low dose of ATG Genzyme (6–8 mg/kg) or ATG
Fresenius [55].
Curr Allergy Asthma Rep           (2019) 19:52 Page 15 of 18    52 
Stem Cell Source in Non-MAC Conditioning
Historically bone marrow has been the preferred stem cell
source for HCT in children due to concerns that peripheral
blood stem cell products led to an increased risk of
GVHD. In Slatter et al.’s report of 160 PID patients who
received uniform conditioning with treosulfan and
fludarabine, a higher level of myeloid chimerism was
found in recipients of PBSC compared to CB and BM,
without an increased risk of grade III/IV acute or chronic
GvHD [26]. This is an important finding particularly for
patients with diseases where a high level of chimerism is
required to achieve complete cure.
Conclusions
The use of RTC and RIC has been a major paradigm shift in
HCT for PID and may have contributed to improved surviv-
al through a reduction in early post-HSCT toxicities.
Almost certainly, long-term toxicities will be reduced, al-
though further data are required to confirm this. However,
the use of antibody-based conditioning regimens is likely to
transform the field in the future. The drive for this has been
that PID can be completely cured by HCT, and as malignan-
cy is rarely a feature of the disease, toxicity from the cura-
tive procedure should be minimized. More recently, new-
born screening for severe combined immunodeficiencies
has meant that these patients are now being identified by
2–3 weeks of age [56]. Rapid transplantation is preferred,
as survival and neurological outcome results are best in
patients with no preexisting infection [57, 58]. As gene
therapy approaches become mainstream treatment, then a
non-toxic conditioning approach followed by an autologous
gene-corrected stem cell procedure should almost eliminate
short- and long-term treatment-related morbidities for pa-
tients with SCID [59, 60]. These conditioning approaches
will have to be modified for combined immunodeficiencies
and gain-of-function diseases where high-level or complete
donor chimerism is required to abolish disease manifesta-
tions [61–64]. However, combinations of antibody-based
regimens and pharmacokinetically targeted reduced low-
toxicity agents may help resolve these issues. The future
for patients with PID looks extremely encouraging.
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